Scientists report studies showing a novel drug repairs myelin and restores nervous system function in a model of multiple sclerosis
December 23, 2024 (Globe Newswire)
Io Therapeutics, Inc., announces presentation of data from studies of its RAR gamma agonist compound IRX5010 in treatment of a mouse model of triple negative breast cancer, demonstrating combination treatment effects with an anti-PDL-1 monoclonal antibody checkpoint inhibitor
December 11, 2024 (Globe Newswire)
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brain Aging
September 18, 2024 (Globe Newswire)
Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis (ALS)
July 16, 2024 (Globe Newswire)
Io Therapeutics, Inc., announces presentation of data on induction of tumor growth inhibiting anti-cancer immune responses in multiple types of cancers by a IRX5010, a novel retinoic acid nuclear receptor agonist compound
July 08, 2024 (Globe Newswire)
Io Therapeutics, Inc., Announces Publication of Data on a Novel Compound Promoting Anti-Cancer Immune Responses
Sept. 12, 2023 (Globe Newswire)